Similar articles

• Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

  Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Cornely OA, et al. N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094. N Engl J Med. 2007. PMID: 17251531 Clinical Trial.
• Posaconazole prophylaxis in hematologic cancer.

  Weiler S, Bellmann R. Weiler S, et al. N Engl J Med. 2007 May 24;356(21):2214; author reply 2215-8. doi: 10.1056/NEJMc070471. N Engl J Med. 2007. PMID: 17522407 No abstract available.
• Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

  Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, Thursky KT, Vincent J, Slavin MA. Ananda-Rajah MR, et al. Haematologica. 2012 Mar;97(3):459-63. doi: 10.3324/haematol.2011.051995. Epub 2011 Nov 4. Haematologica. 2012. PMID: 22058198 Free PMC article.
• Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?

  Rüping MJ, Vehreschild JJ, Cornely OA. Rüping MJ, et al. Leuk Lymphoma. 2010 Jan;51(1):20-6. doi: 10.3109/10428190903242602. Leuk Lymphoma. 2010. PMID: 20017598 Review.
• Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point.

  Gonzalez AV, Ullmann AJ, Almyroudis NG, Segal BH. Gonzalez AV, et al. J Natl Compr Canc Netw. 2008 Feb;6(2):175-82. doi: 10.6004/jnccn.2008.0014. J Natl Compr Canc Netw. 2008. PMID: 18319049 Review.